CEACAM5 and colorectal carcinoma: The bispecific antibody cibisatamab (binds to CD3 and CEA) has antitumour activity with radiological shrinkage in 11% of 36 patients treated with cibisatamab monotherapy and in 50% of 10 patients treated with cibisatamab and PD‐L1‐inhibiting antibodies on metastatic CEA positive colorectal carcinomas in a recent phase I study.11, 12